1
|
Colley CS, Popovic B, Sridharan S, Debreczeni JE, Hargeaves D, Fung M, An L, Edwards B, Arnold J, England E, Eghobamien L, Sivars U, Flavell L, Renshaw J, Wickson K, Warrener P, Zha J, Bonnell J, Woods R, Wilkinson T, Dobson C, Vaughan TJ. Structure and characterization of a high affinity C5a monoclonal antibody that blocks binding to C5aR1 and C5aR2 receptors. MAbs 2018; 10:104-117. [PMID: 28952876 PMCID: PMC5800367 DOI: 10.1080/19420862.2017.1384892] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
C5a is a potent anaphylatoxin that modulates inflammation through the C5aR1 and C5aR2 receptors. The molecular interactions between C5a-C5aR1 receptor are well defined, whereas C5a-C5aR2 receptor interactions are poorly understood. Here, we describe the generation of a human antibody, MEDI7814, that neutralizes C5a and C5adesArg binding to the C5aR1 and C5aR2 receptors, without affecting complement-mediated bacterial cell killing. Unlike other anti-C5a mAbs described, this antibody has been shown to inhibit the effects of C5a by blocking C5a binding to both C5aR1 and C5aR2 receptors. The crystal structure of the antibody in complex with human C5a reveals a discontinuous epitope of 22 amino acids. This is the first time the epitope for an antibody that blocks C5aR1 and C5aR2 receptors has been described, and this work provides a basis for molecular studies aimed at further understanding the C5a-C5aR2 receptor interaction. MEDI7814 has therapeutic potential for the treatment of acute inflammatory conditions in which both C5a receptors may mediate inflammation, such as sepsis or renal ischemia-reperfusion injury.
Collapse
MESH Headings
- Antibodies, Monoclonal/chemistry
- Antibodies, Monoclonal/genetics
- Antibodies, Monoclonal/immunology
- Antibodies, Monoclonal/pharmacology
- Antibody Affinity
- Antibody Specificity
- Binding Sites, Antibody
- Complement C5a/antagonists & inhibitors
- Complement C5a/chemistry
- Complement C5a/immunology
- Complement C5a/metabolism
- Epitope Mapping/methods
- Epitopes
- HEK293 Cells
- Humans
- Protein Binding
- Protein Conformation
- Protein Engineering
- Receptor, Anaphylatoxin C5a/antagonists & inhibitors
- Receptor, Anaphylatoxin C5a/chemistry
- Receptor, Anaphylatoxin C5a/immunology
- Receptor, Anaphylatoxin C5a/metabolism
- Receptors, Chemokine/antagonists & inhibitors
- Receptors, Chemokine/chemistry
- Receptors, Chemokine/immunology
- Receptors, Chemokine/metabolism
- Structure-Activity Relationship
Collapse
Affiliation(s)
- Caroline S. Colley
- Antibody Discovery and Protein Engineering, MedImmune Ltd, Cambridge, UK
- CONTACT Caroline S. Colley Antibody Discovery and Protein Engineering, MedImmune Ltd, Granta Park, Cambridge, CB21 6GH, UK
| | - Bojana Popovic
- Antibody Discovery and Protein Engineering, MedImmune Ltd, Cambridge, UK
| | | | | | | | - Michael Fung
- Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, USA
| | - Ling–Ling An
- Respiratory, Inflammation and Autoimmunity, MedImmune LLC, Gaithersburg, MD, USA
| | - Bryan Edwards
- Antibody Discovery and Protein Engineering, MedImmune Ltd, Cambridge, UK
| | - Joanne Arnold
- Antibody Discovery and Protein Engineering, MedImmune Ltd, Cambridge, UK
| | - Elizabeth England
- Antibody Discovery and Protein Engineering, MedImmune Ltd, Cambridge, UK
| | - Laura Eghobamien
- Respiratory, Inflammation and Autoimmunity, MedImmune Ltd, Cambridge, UK
| | - Ulf Sivars
- Translational Biology, IMED RIA Biotech Unit, AstraZeneca, Gothenburg, Sweden
| | - Liz Flavell
- Discovery Sciences, AstraZeneca R&D, Cambridge, UK
| | | | - Kate Wickson
- Discovery Sciences, AstraZeneca R&D, Cambridge, UK
| | - Paul Warrener
- Infectious Diseases, MedImmune LLC, Gaithersburg, MD, USA
| | - Jingying Zha
- Infectious Diseases, MedImmune LLC, Gaithersburg, MD, USA
| | | | - Rob Woods
- Antibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, MD, USA
| | - Trevor Wilkinson
- Antibody Discovery and Protein Engineering, MedImmune Ltd, Cambridge, UK
| | - Claire Dobson
- Antibody Discovery and Protein Engineering, MedImmune Ltd, Cambridge, UK
| | - Tristan J. Vaughan
- Antibody Discovery and Protein Engineering, MedImmune Ltd, Cambridge, UK
| |
Collapse
|